Durometry for the assessment of skin disease in systemic sclerosis.

OBJECTIVE To examine the validity of a durometer to objectively measure skin hardness in systemic sclerosis (SSc), and to compare digital durometry with the modified Rodnan skin score (MRSS) and ultrasonography. METHODS Patients with SSc and healthy controls underwent durometry measurements in 3 assessments: a Latin square experiment to establish durometry's intra- and interobserver reliability compared with skin scoring (5 SSc, 1 control); a longitudinal cohort to assess sensitivity to change in skin hardness (13 SSc, 5 controls); and an ultrasound cohort to evaluate correlation between durometry, ultrasound-measured skin thickness, and clinical skin scoring (30 SSc, 12 controls). RESULTS Intraobserver reproducibility was higher for durometry than for clinical skin scoring (intraclass correlation coefficient [ICC] 0.97 versus 0.85), whereas interobserver reproducibility was similar (0.75 versus 0.73). Interobserver reproducibility of durometry was good for all body areas (ICC 0.61-0.85), but for skin scoring it was moderate in the legs (0.51) and poor in the abdomen (0.08), feet (0.09), and fingers (0.27). Durometry scores correlated with clinical skin scores (Latin square: r = 0.44, P = 0.03; longitudinal cohort: r = 0.81, P < 0.001) and ultrasound-measured skin thickness (hands: r = 0.58, forearms: r = 0.63, upper arms: r = 0.40; P < or = 0.001 for all). Uninvolved skin in patients with SSc was harder than skin from controls (mean +/- SD 23 +/- 7 durometer units [DU] versus 19 +/- 6 DU; P < 0.0001). Finally, there was a strong correlation between change in MRSS and change in durometry score (r = 0.77, P = 0.002). CONCLUSION Durometer-measured skin hardness correlates well with MRSS and ultrasound-measured skin thickness, provides greater reliability than MRSS, and is sensitive to changes in skin hardness over time. Durometry should be considered for use in clinical therapeutic SSc trials.

[1]  J. Seibold,et al.  Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin". , 2010, Arthritis and rheumatism.

[2]  P. Lachenbruch,et al.  Skin score. A semiquantitative measure of cutaneous involvement that improves prediction of prognosis in systemic sclerosis. , 2010, Arthritis and rheumatism.

[3]  M. Mayes,et al.  Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial. , 2004, Arthritis and rheumatism.

[4]  T. Moore,et al.  Seventeen-point dermal ultrasound scoring system--a reliable measure of skin thickness in patients with systemic sclerosis. , 2003, Rheumatology.

[5]  M. Suarez‐Almazor,et al.  Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. , 2003, The Journal of rheumatology.

[6]  T. Medsger,et al.  Improvement in skin thickening in systemic sclerosis associated with improved survival. , 2001, Arthritis and rheumatism.

[7]  N. Bellamy,et al.  A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. , 2001, Arthritis and rheumatism.

[8]  Richard W. Martin,et al.  Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. , 2000, Arthritis and rheumatism.

[9]  L. Moreland,et al.  Recombinant Human Relaxin in the Treatment of Scleroderma , 2000, Annals of Internal Medicine.

[10]  Richard W. Martin,et al.  High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. , 1999, Arthritis and rheumatism.

[11]  Clements Pj.  Measuring disease activity and severity in scleroderma. , 1995, Current opinion in rheumatology.

[12]  I. Braverman,et al.  Reproducible measurements to quantify cutaneous involvement in scleroderma. , 1995, Archives of dermatology.

[13]  N. Bellamy,et al.  Variability of skin scores and clinical measurements in scleroderma. , 1995, The Journal of rheumatology.

[14]  M. Fujimoto,et al.  Ultrasound measurement of skin thickness in systemic sclerosis. , 1995, British journal of rheumatology.

[15]  A. Silman,et al.  Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. , 1993, The Journal of rheumatology.

[16]  P. Lachenbruch,et al.  The course of skin involvement in systemic sclerosis over three years in a trial of chlorambucil versus placebo. , 1993, Arthritis and rheumatism.

[17]  V. Falanga,et al.  Use of a durometer to assess skin hardness. , 1993, Journal of the American Academy of Dermatology.

[18]  M. Corkill,et al.  Reliability of skin score in scleroderma. , 1993, British journal of rheumatology.

[19]  A. Silman,et al.  RELIABILITY OF SKIN INVOLVEMENT MEASURES IN SCLERODERMA , 1992 .

[20]  A. Masi.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). , 1980, Bulletin on the rheumatic diseases.

[21]  James F. Fries,et al.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. , 1980, Arthritis and rheumatism.

[22]  G. Rodnan,et al.  Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. , 1979, Arthritis and rheumatism.

[23]  Hyon K. Choi,et al.  Intake of purine-rich foods, protein, and dairy products and relationship to serum levels of uric acid: the Third National Health and Nutrition Examination Survey. , 2005, Arthritis and rheumatism.